Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon


Regulatory News


Result of General Meeting

Fri, 12th Oct 2018 11:05


RNS Number : 9009D
Synairgen plc
12 October 2018

Correction: In the Company's RNS published at 10.29am this morning (RNS number 8911D) the time the admission of the New Ordinary Shares was incorrectly stated as being at 8.00 a.m. on Monday 15 September 2018. The correct time for the admission of the New Ordinary Shares is 8.00 a.m. on Monday 15 October 2018 and this has been corrected in the replacement RNS set out below. All other content remains unchanged.

Synairgen plc

('Synairgen' or the 'Company')

Result of General Meeting

Further to Synairgen's announcement of 25 September 2018, the Company is pleased to announce today the passing of the Resolutions at the General Meeting held earlier today. The Placing and Subscription remain conditional on Admission of the New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Monday 15 October 2018.

With effect from Admission, the Company will have 109,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Following Admission, the shareholdings of the below Directors of the Company, who participated in the Fundraise, are as follows:

Director

Ordinary Shares held prior to the Fundraise

Ordinary Shares subscribed for in the Fundraise

Ordinary Shares held after the Fundraise

Percentage of the Enlarged Issued Share Capital held

Richard Marsden

154,432

156,250

310,682

0.28%

Dr Phillip Monk

183,439

46,875

230,314

0.21%

John Ward

276,506

62,500

339,006

0.31%

Capitalised terms in the text of this announcement have the meanings given to them in the Company's circular dated 26 September 2018.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Max Bullen-Smith (Corporate Finance)

Alice Lane (ECM)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott / Sukaina Virji / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

Notes for Editors

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.

Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a 5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Marsden

2.

Reason for the Notification

a)

Position/status

PDMR - CEO

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 p each

Identification code

GB00B0381Z20

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

16 pence

156,250

d)

Aggregated information:

Aggregated volume

Price

N/A, single transaction as per 4c above

e)

Date of the transaction

12 October 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr. Phillip Monk

2.

Reason for the Notification

a)

Position/status

PDMR - Chief Scientific Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 p each

Identification code

GB00B0381Z20

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

16 pence

46,875

d)

Aggregated information:

Aggregated volume

Price

N/A, single transaction as per 4c above

e)

Date of the transaction

12 October 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Ward

2.

Reason for the Notification

a)

Position/status

PDMR - Finance Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 p each

Identification code

GB00B0381Z20

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

16 pence

62,500

d)

Aggregated information:

Aggregated volume

Price

N/A, single transaction as per 4c above

e)

Date of the transaction

12 October 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ROMGGGPUUUPRGUP


Related Shares:
Synairgen (SNG)



Back to Regulatory News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.